Overview
GLOW Blend is an advanced tri-peptide regenerative formula combining GHK-Cu, TB-500, and BPC-157 in a single vial.
What problem it targets: It targets comprehensive skin rejuvenation, scar remodeling, hair follicle revival, and joint/tendon wear by merging aesthetic repair with deep soft-tissue healing.
What It Does
• Integrates three distinct repair mechanisms: BPC-157 drives rapid localized blood vessel growth, TB-500 coordinates cell migration via actin regulation, and GHK-Cu upregulates over 4,000 tissue-repair genes.
• Rebuilds full-thickness collagen and connective tissue: Promotes dermal collagen and elastin synthesis while simultaneously repairing underlying tendons, ligaments, and fascia.
• Dismantles stubborn scar tissue and calms inflammation: Accelerates wound healing and remodels fibrous scar tissue into supple, functional tissue.
• Realistic expectations: Delivers noticeable improvements in skin tone, elasticity, and localized joint aches within 2 to 4 weeks. Injectable copper can cause mild local stinging; rotating sites is recommended.
Reconstitution
| Vial size | BAC water / Solvent | Concentration |
|---|---|---|
| 70 mg | + 5 mL | GHK-Cu 10 mg/mL |
Protocol
| Phase | Frequency | Dose | Notes |
|---|---|---|---|
| Week 1 | Daily | 1 mg | Loading. 1 mg GHK-Cu + 0.2 mg BPC-157 + 0.2 mg TB-500 per dose. |
| Week 2 | Daily | 1.5 | Ramp. 1.5 mg GHK-Cu + 0.3 mg BPC + 0.3 mg TB per dose. mg |
| Weeks 3–8 | Daily | 2 mg | Working dose. 2 mg GHK-Cu + 0.4 mg BPC + 0.4 mg TB per dose. |
| Aggressive | Daily (AM + | 3–4 | Bump here ONLY if 2+ weeks at 2 mg with zero injection-site issues AND a specific high-demand goal. Start at 3 mg (= 0.6 |
| PM split) | mg | 40u | |
| Off | 4 weeks | – | Mandatory copper-accumulation washout. Do not skip, especially after an Aggressive phase. Cycle: 8 weeks on / 4 weeks off, matches GHK-Cu copper-accumulation limits. Timing: Daily SubQ, anytime; same as the Wolverine base. By sex: Unisex (GHK-Cu + BPC-157 + TB-500 repair / skin), same protocol for men and women, no cycle effect. Avoid in pregnancy. |
Handling & Stacking
- Freeze-dried: -4°F.
- Reconstituted: 36–46°F, protect from light.
- Best used within about 2–4 weeks, kept cold and dark (structure-based estimate, no published data); copper oxidizes with no visible colour change, so use it sooner rather than later.
- Broad tissue repair, skin quality improvement, and anti-inflammatory effects build over the 8-week cycle.
- 4-week washout follows.
- Supply math 70mg → 2 vials (8-wk @ 2 mg × 7/wk).
- 70 mg vial covers ~half of an 8-week cycle at 2 mg/day; reconstituted shelf life ~28 days.
- Aggressive 3–4 mg/day depletes the vial faster but stays inside the discard window.
Safety & Patient Education
- Active or suspected malignancy.
- TB-500 is angiogenic systemically; BPC-157 drives angiogenesis locally via VEGF; copper is an angiogenesis cofactor, so all three point the same way.
- Theoretical, there’s no human evidence they cause cancer, but they can’t tell healthy tissue from a tumour you don’t know about.
- Screen age-appropriately before a long run; stop for any new lump.
- Wilson’s disease, copper dysregulation, copper allergy (GHK-Cu component) Active bleeding or recent hemorrhagic stroke (TB-500 vascular effects) Pregnancy, lactation
- Combines three compounds with no human RCT data on the blend itself.
- Quality varies by compounder; request COA listing each component’s purity.
- GHK-Cu: extended continuous use can cause copper accumulation, the 6-week off period is critical.
- BPC-157: FDA Category 2 in 2023; compounding from bulk substances is restricted.
- TB-500: no published human efficacy trials; theoretical malignancy risk via angiogenesis.
- BPC-157 & TB-500 were both RECOMMENDED for the 503A bulks list by PCAC (8–6 each, Jul 2026; advisory, non-binding).
- Compound-specific: hsCRP (baseline + end) Serum copper and ceruloplasmin if cycles extend beyond 6 weeks (GHK-Cu accumulation) Out of range?
- Rising serum copper / ceruloplasmin = copper is accumulating → pause and re-dose lower.
- Three-peptide blend: any single-component contraindication applies to the whole blend.
- Cycle discipline matters more than dose: 6 weeks on / 6 weeks off is the canonical pattern.
- Inject SubQ near target tissue.
- Rotate sites to reduce GHK-Cu sting.
